Oculis is a clinical stage biotechnology company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the lives of patients worldwide.
Innovative Topical therapies for millions of patients worldwide
The Oculis strategy is to build a specialty ophthalmology company unlike any other. Our plan is to:
- Further advance our lead candidate, OC-118, for commercialization as a new therapeutic option for DME patients
- Develop a clinical pipeline of topical treatments for back- and front-of the-eye disease based on internal development with our proprietary SNP technology and via complementary in-licensed assets
OC-118 A potential paradigm shift in DME treatment
Our most advanced product candidate based on SNP technology is OC-118, which is in clinical trials in patients with DME and in planning phase for potential front-of-the-eye indications.
If approved in DME, it has the potential to provide a new option for patients for whose current therapies are limited to intravitreal injections or implants.
Taking treatment from injections to drops for Back-of-the-Eye Diseases
Our novel technology provides an unprecedented technical advancement in ocular drug delivery, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants.